ADJUNCTIVE PERAMPANEL RCT FOR PGTC SEIZURES

Autor:	Francesco Bibbiani, Terence J. O'Brien, Christian Brandt, Xuefeng Wang, Jacqueline A. French, Antonio Laurenza, Bree DiVentura, Gregory L. Krauss, Robert T. Wechsler, Eugen Trinka, Anna Patten
Rok vydání:	2015
Předmět:	Seizure frequency Randomization business.industry Antagonist Placebo law.invention Psychiatry and Mental health Perampanel chemistry.chemical_compound Randomized controlled trial chemistry law Concomitant Anesthesia Medicine Surgery Neurology (clinical) business
Zdroj:	Journal of Neurology, Neurosurgery & Psychiatry. 86:e4.145-e4
ISSN:	1468-330X 0022-3050
DOI:	10.1136/jnnp-2015-312379.54
Popis:	We assessed efficacy and safety of perampanel (selective noncompetitive AMPA receptor antagonist) for primary generalised tonic-clonic (PGTC) seizures. Patients ≥12years with confirmed IGE; ≥3 PGTC seizures/8 weeks prior to randomization; receiving 1–3 concomitant AEDs were recruited. Trial consisted of 4–week screening; 4–8 week Baseline, 1:1 Randomization (perampanel titrated over 4 weeks to 8mg or highest tolerated dose versus placebo), 13–week Maintenance, 4–week Follow-up and Extension Phases. 164 patients were randomized; full analysis set included 81 patients each on perampanel and placebo. Median percent change in PGTC seizure frequency/28 days during Titration/Maintenance versus Baseline was –76.5% with perampanel versus –38.4% placebo; P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::272f5f87866b28d35505c808fb33fa98 https://doi.org/10.1136/jnnp-2015-312379.54 Zobrazit plný text záznamu